About Ipsen
Ipsen is a company based in Boulogne-billancourt (France) founded in 1929. The company has 5,360 employees as of December 31, 2024. Ipsen has completed 9 acquisitions, including Albireo Pharma, Canbex Therapeutics and Clementia. Ipsen offers products and services including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products. Ipsen operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Boulogne-billancourt, France
- Employees 5360 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ipsen Sa
-
Annual Revenue
$3.53 B (USD)8.73as on Dec 31, 2024
-
Net Profit
$359.36 M (USD)-46.32as on Dec 31, 2024
-
EBITDA
$1.08 B (USD)9.6as on Dec 31, 2024
-
Latest Funding Round
$617.66 K (USD), Grant
Dec 18, 2023
-
Investors
Qualium Investissement
& 1 more
-
Employee Count
5360
as on Dec 31, 2024
-
Investments & Acquisitions
Albireo Pharma
& 8 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ipsen
Ipsen is a publicly listed company on the EURONEXT with ticker symbol IPN in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ipsen
Ipsen offers a comprehensive portfolio of products and services, including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products.
Treatments for cancers like neuroendocrine tumors
Drugs for rare conditions such as liver diseases
Medicines for debilitating neurological conditions
People of Ipsen
Unlock access to complete
Unlock access to complete
Leadership Team
165 people
Software Development Team
160 people
Product Management Team
44 people
Human Resources and Administration
41 people
Finance and Accounting
36 people
Senior Team
32 people
Sales and Marketing
30 people
Operations Team
29 people
Unlock access to complete
Funding Insights of Ipsen
Investors in Ipsen
Ipsen has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Qualium Investissement and Ministry of Economy, Finance and Industrial and Digital Sovereignty.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Ipsen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ipsen
Ipsen has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include Albireo Pharma, Canbex Therapeutics and Clementia.
Investment portfolio details for Ipsen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for cancer treatment are developed by Kartos Therapeutics.
|
Locked | Locked | 2018 | Locked | |
|
ImCheck Therapeutics is focused on immune system modulation innovation.
|
Locked | Locked | 2015 | Locked | |
|
Information on liposome injections for pancreatic cancer is provided.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Ipsen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Ipsen
Detailed financials for Ipsen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ipsen Comparisons
Peer comparison for Ipsen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ipsen
Ipsen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Ipsen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ipsen
Complete news archive for Ipsen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ipsen
Ipsen was founded in 1929 and raised its 1st funding round 69 years after it was founded.
Ipsen is headquartered in Boulogne-billancourt, France. It is registered at Boulogne-billancourt, Hauts-de-seine, France.
As of Dec 31, 2024, the latest employee count at Ipsen is 5,360.
Annual revenue of Ipsen is $3.53B as on Dec 31, 2024.
Ipsen is a mid-sized biopharmaceutical company focused on innovation and specialty care to improve patient health outcomes. The company develops and commercializes transformative medicines in oncology, rare disease, and neuroscience. With a commitment to precision focus on RD, Ipsen builds a pipeline at every stage from discovery to late-stage clinical development.
Ipsen's top competitors include Merck, Roivant Sciences and AbbVie.
Ipsen offers Oncology Medicines, Rare Disease Treatments, and Neuroscience Products.
Yes, Ipsen is publicly traded on EURONEXT under the ticker symbol IPN.
Ipsen has made 9 acquisitions, including Albireo Pharma, Canbex Therapeutics, and Clementia.
Ipsen has 2 investors. Key investors include Qualium Investissement, and Ministry of Economy, Finance and Industrial and Digital Sovereignty.
The ticker symbol of Ipsen is IPN on EURONEXT.